Why the study?
Patients with hypertriglyceridemia may require additional therapy to reduce residual ASCVD risk, and novel agents could provide options for patients intolerant of existing therapies.
What is the recent evidence for pipeline TG-lowering agents in patients with hypertriglyceridemia?
What is the recent evidence for pipeline TG-lowering agents in patients with hypertriglyceridemia?
While icosapent ethyl remains the only FDA-approved therapy for CV risk reduction in hypertriglyceridemia, novel agents like apoC-III and ANGPTL3 inhibitors are in development.
Answers are grounded in this paper and cite their sources.
Icosapent ethyl remains sole approved CV risk reducer in hypertriglyceridemia; leaves open role of pipeline agents pending phase 3 data.
Background The 2018 American College of Cardiology/American Heart Association (ACC/AHA) guidelines and 2021 ACC Expert Consensus Decision Pathway recommend nonpharmacological interventions and initiation of statin therapy for patients with moderate hypertriglyceridemia and addition of fibrates or omega-3 fatty acids in severe hypertriglyceridemia. Although the association between triglyceride (TG) lowering and atherosclerotic cardiovascular disease (ASCVD) risk reduction remains controversial, patients with hypertriglyceridemia may represent a subgroup that require additional therapy to further reduce residual ASCVD risk. Moreover, medications that target novel pathways could provide alternative options for patients who are intolerant of existing therapies or doses needed to provide adequate triglyceride lowering. Objective: Assess recent evidence for TG-lowering agents including omega-3 fatty acid-based therapies, PPARα modulators, apoC-III mRNA antisense inhibitors, angiopoietin-like 3 (ANGPTL3) antibodies, and herbal supplements. Methods: A literature search was performed using PubMed with hypertriglyceridemia specified as a MeSH term or included in the title or abstract of the article along with each individual agent. For inclusion, trials needed to have a primary or secondary outcome of TG levels or TG lowering. Conclusion: Currently, the only US Food and Drug Administration approved medication for CV risk reduction in patients with hypertriglyceridemia is icosapent ethyl. Results from phase 3 trials for CaPre, pemafibrate, and volanesorsen as well as additional evidence for pipeline pharmacotherapies with novel mechanisms of action (e.g., ApoC-III mRNA antisense inhibitors and ANGPTL3 antibodies) will help to guide future pharmacotherapy considerations for patients with hypertriglyceridemia.
No takes yet. Share an insight, caveat, or question.
Xu et al. (2021) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: